From the youngest person living with Rett syndrome, or Fragile X syndrome, to the oldest person experiencing Alzheimer's disease, or Parkinson's disease dementia, Anavex Life Sciences has developed an intergenerational therapeutic discovery platform. 

 

In the age of inclusivity, Anavex Life Sciences recognizes that its' vision as a company is only made possible if patients have equitable access to healthcare, regardless of age, biological sex, gender, ethnicity, racial classification, etc. and is proud of the team's consciously inclusive approach to clinical trial design and development.

 

For example, the ANAVEX®2-73 (NCT03758924) trial, a U.S. based study, enrolled adult women 18 to 45 years of age with Rett syndrome, a progressive rare disease that is pediatric onset. Traditionally, biopharmaceutical companies dedicated to solving CNS conditions primarily focus resources on developing treatments for pediatric populations. This historical dynamic is due in large part to the misconception that too much time has passed for members of the adult population living with neurodevelopmental disorders and that there is nothing that can be done to improve their condition.

 

Aside from ANAVEX®2-73 showing significant improvement in key domains with no serious adverse events for a variety of CNS conditions across an intergenerational population, the ANAVEX®2-73 (NCT03758924) trial's participants, all being exclusively adult women 18 to 45 years of age, established an important precedence within the rare disease drug development ecosystem. 

​

The vision of Anavex Life Sciences is only made possible if patients have equitable access to healthcare. As a result, the team at Anavex Life Sciences takes its role in helping to address health equity across the healthcare institutional continuum seriously. Through inclusive, person-focused approaches to clinical trial design and the sheer determination to improve the lives of people of all ages and backgrounds impacted by CNS disorders,  the team at Anavex Life Sciences is working diligently to bring quality of life improving treatments for a widespread variety of neurodevelopmental and neurodegenerative disorders.

 

From infants to the elderly, Anavex Life Sciences remains dedicated to addressing the devastating impact of neurological disorders through the development of its' proprietary SIGMACEPTOR™ discovery platform.

 

As a large body of evidence indicates that sigma-1 receptors (SIGMAR1) are important drug targets for a number of neurological disorders, the team at Anavex Life Sciences is proud of its accomplishments thus far and looks forward to continuing the work required to achieve its' life-saving therapeutic discovery goals.

​

​